The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | LINKER-MM1: promising safety and efficacy of linvoseltamab in R/R multiple myeloma
Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares findings from the LINKER-MM1 study (NCT03761108), evaluating step-up dosing of linvoseltamab in relapsed/refractory (R/R) multiple myeloma (MM). After a median follow-up of 8.1 months, the overall response rate (ORR) was 69%, with an estimated 9-month duration of response (DoR) being 87% and a 9-month progression-free survival (PFS) of 73%. There were no new safety concerns, with cytokine release syndrome (CRS) being mainly low-grade and manageable. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Consultancy; AbbVie: Consultancy; Janssen: Consultancy, Research Funding; Amgen: Research Funding; Regeneron: Consultancy, Research Funding; Allogene Thereapeutics: Consultancy; Takeda Pharmaceuticals: Consultancy, Research Funding; Monte Rosa Therapeutics: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy; GlaxoSmithKline: Consultancy, Research Funding; Genentech: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding.
